Abstract
In a longitudinal prospective experimental study to study some pro-inflammatory chemokines, cytokines and neurodestruction indicators in patients with the first episode of schizophrenia during therapy with first-and second-generation antipsychotics, 40 patients with a diagnosis of F20.09 were examined, of which 20 took haloperidol and 20 risperidone. CCL2, sTREM-1, sTREM-2, TGF-β1, VILIP-1 and sRAGE in the blood serum by flow fluorimetry before the starts of therapy and after 8 weeks were determined. Before treatment, the CCL2 value exceeded the control values by 65%, sTREM-1 – by 120%, VILIP-1 – by 60%, sRAGE – by 79%. After 8 weeks of therapy with haloperidol, the blood levels of CCL2, VILIP-1, TGF-β1 continued to increase and sRAGE decreased. During the treatment with risperidone, an increase in the content of only VILIP-1 was noted, with a decrease in CCL2, TGF-β1 and sRAGE. The results indicate an increase in the central nervous system damage during the manifestation of schizophrenia, while therapy with risperidone in comparison with haloperidol has a beneficial effect on a greater number of the studied parameters.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
